Atezolizumab Plus Cabozantinib vs Docetaxel for Metastatic NSCLC After Checkpoint Inhibition and Chemotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy
J. Clin. Oncol 2024 Mar 29;[EPub Ahead of Print], J Neal, N Pavlakis, SW Kim, Y Goto, SM Lim, G Mountzios, E Fountzilas, A Mochalova, DC Christoph, A Bearz, X Quantin, R Palmero, V Antic, E Chun, TR Edubilli, YC Lin, M Huseni, M Ballinger, V Graupner, D Curran, P Vervaet, T Newsom-DavisFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.